• Home
  • Aktuelles
  • Why is biosimilar adoption slow in the US, and can something be done to boost uptake?
Beteiligte Personen

Litigation & Dispute Resolution partner Christopher Mikson (Washington DC) was quoted in this article.

Beratungsfelder

Praxis –
Branchen –

Aktuelles

Alle anzeigen